A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.12.001
Abstract: BACKGROUND Metastatic soft tissue sarcomas (STSs) management remains an unmet medical need. We assessed the activity and safety of regorafenib in patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib.… read more here.
Keywords: non adipocytic; activity safety; versus; placebo ... See more keywords